RecallRadar

FDA Drug recall D-0097-2023

Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59)…

On 2023-01-11 the FDA classified a Class II recall of Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59)… by Pfizer, citing lack of assurance of sterility: Bags have the potential to leak.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0097-2023
ClassificationClass II
Statuscompleted
Initiated2022-12-29
Published2023-01-11
Last updated2026-09-13 11:52 UTC
CompanyPfizer
DistributionUS

Product

Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,

Reason

Lack of assurance of sterility: Bags have the potential to leak.

Identifiers

ndc0409-7620-13
ndc0409-7620-03
ndc0409-7620-49
ndc0409-7620-59
ndc0409-1005-01
ndc0409-1005-20
ndc0409-2222-01
ndc0409-2222-12
code_infoLot: 5935283, Exp. 12/01/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0097-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.